Cinzia Pilo

Dr. Cinzia Pilo

Fondazione REB ETS, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
Livio ProvenziLivio Provenzi
Livio Provenzi
MGMichelle A. Ovalles Gomez
Michelle A. Ovalles Gomez
SFSimona Frassone
Simona Frassone
CPCinzia Pilo
Cinzia Pilo
EAElisa ANGIOLINI
Elisa ANGIOLINI
SBSerena Barello
Serena Barello
Climate change threatens environmental stability and human health, with limited research on younger children’s perceptions. This study examines Italian primary school children’s views on climate change to guide educational and policy strategies. Surveying 973 children (5–11 years) from different regions, findings showed high awareness (93%) and concern (63%) about climate change. Regional differences indicated greater concern in the south. Gender disparities revealed females were more concerned and experienced more sleep difficulties. Younger children had stronger emotional responses, while older ones showed increased pro-environmental behaviors. Despite moderate self-confidence in effecting change, a strong sense of responsibility and trust in adults was prevalent. These results highlight the need for early, continuous climate education tailored to regional, age, and gender-specific needs. Addressing children’s views on climate change can help educators and policymakers foster resilience and proactive attitudes, supporting the development of informed and engaged future stewards of the planet.

20 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LDLeonardo Detto
Leonardo Detto
NRNicole Rinaldi
Nicole Rinaldi
FRFlaminia Ruberti
Flaminia Ruberti
CPCinzia Pilo
Cinzia Pilo
Susanna EspositoSusanna Esposito
Susanna Esposito
Background: Inherited epidermolysis bullosa (EB) comprises monogenic disorders characterised by tissue fragility, recurrent blistering, chronic wounds and multisystem complications. Although multidisciplinary supportive care remains fundamental, it cannot correct the molecular defect or prevent cumulative tissue damage. This narrative review examines emerging disease-modifying therapies for inherited EB, emphasising their application in clinical practice. Methods: Pub-Med/MEDLINE was searched using terms relating to EB subtypes and pharmacological, gene-, RNA-, protein-, cell- and genome-editing therapies. Reference lists, clinical guidelines, consensus statements and regulatory documents were also examined. Clinical studies and preclinical investi-gations were synthesised qualitatively; no meta-analysis was performed. Results: Recent advances have expanded treatment beyond conventional wound care. Oleogel-S10 enhances endogenous wound healing independently of genotype, whereas beremagene geperpavec delivers functional COL7A1 copies directly to dystrophic EB wounds. Prademagene zamikeracel combines ex vivo correction of autologous keratinocytes with epidermal grafting, offering potentially sustained clo-sure of selected chronic wounds. Nevertheless, these treatments remain predominantly local and do not fully address generalised skin fragility or extracutaneous disease. Mesenchymal stromal cells, haematopoietic stem cell transplantation, recombinant type VII collagen, RNA-based treatments and genome editing may provide broader or more durable benefits, but evidence remains limited and concerns regarding delivery, safety, durability and accessibility persist. Conclusion: Precision and regenerative therapies are transforming EB management but remain complementary to multi-disciplinary supportive care. Clinical evaluation should extend beyond wound closure to include pain, function, growth, quality of life and caregiver burden. Long-term surveillance and personal-ised combination strategies are essential to determine whether early treatment can safely alter the natural history of EB.

1 January 2023
Verified
Book Chapter
Open access
LBLaura Benedan
Laura Benedan
ADAngela Digrandi
Angela Digrandi
PMPaolo Mariani
Paolo Mariani
CPCinzia Pilo
Cinzia Pilo
MZMariangela Zenga
Mariangela Zenga
In this work, we show a narrative review conserning instruments to measure the quality of Life in Health Care from a patients point of view. In particular, we pay attention on the construction of questionnaire and on the choice of the areas/settings (physical, emotional, social, functional, economical,...).

16 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LDLeonardo Detto
Leonardo Detto
NRNicole Rinaldi
Nicole Rinaldi
FRFlaminia Ruberti
Flaminia Ruberti
CPCinzia Pilo
Cinzia Pilo
Susanna EspositoSusanna Esposito
Susanna Esposito
Background: Inherited epidermolysis bullosa (EB) comprises monogenic disorders characterised by tissue fragility, recurrent blistering, chronic wounds and multisystem complications. Although multidisciplinary supportive care remains fundamental, it cannot correct the molecular defect or prevent cumulative tissue damage. This narrative review examines emerging disease-modifying therapies for inherited EB, emphasising their application in clinical practice. Methods: PubMed/MEDLINE was searched using terms relating to EB subtypes and pharmacological, gene-, RNA-, protein-, cell- and genome-editing therapies. Reference lists, clinical guidelines, consensus statements and regulatory documents were also examined. Clinical studies and preclinical investigations were synthesised qualitatively; no meta-analysis was performed. Results: Recent advances have expanded treatment beyond conventional wound care. Oleogel-S10 enhances endogenous wound healing independently of genotype, whereas beremagene geperpavec delivers functional COL7A1 copies directly to dystrophic EB wounds. Prademagene zamikeracel combines ex vivo correction of autologous keratinocytes with epidermal grafting, offering potentially sustained closure of selected chronic wounds. Nevertheless, these treatments remain predominantly local and do not fully address generalised skin fragility or extracutaneous disease. Mesenchymal stromal cells, haematopoietic stem cell transplantation, recombinant type VII collagen, RNA-based treatments and genome editing may provide broader or more durable benefits, but evidence remains limited, and concerns regarding delivery, safety, durability and accessibility persist. Conclusion: Precision and regenerative therapies are transforming EB management but remain complementary to multidisciplinary supportive care. Clinical evaluation should extend beyond wound closure to include pain, function, growth, quality of life and caregiver burden. Long-term surveillance and personalised combination strategies are essential to determine whether early treatment can safely alter the natural history of EB.